Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Trial Investigating the Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Women Aged 35-42 Years Undergoing Assisted Reproductive Technology
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Follitropin delta (Primary)
- Indications Female infertility
- Focus Registrational; Therapeutic Use
- Acronyms RITA-2
- Sponsors Ferring Pharmaceuticals
- 28 Jun 2021 Status changed from active, no longer recruiting to completed.
- 02 Sep 2020 Planned End Date changed from 1 Jul 2021 to 1 Jun 2021.
- 02 Sep 2020 Planned primary completion date changed from 1 Jul 2021 to 1 Jun 2021.